Kura Oncology And Kyowa Kirin Announce Blood Publication Of Phase 1 Ziftomenib Combination Data Showing 87% ORR In Venetoclax-Naïve R/R NPM1-m AML

Loading news article.

Kura Oncology And Kyowa Kirin Announce Blood Publication Of Phase 1 Ziftomenib Combination Data Showing 87% ORR In Venetoclax-Naïve R/R NPM1-m AML | WAPE

Kura Oncology And Kyowa Kirin Announce Blood Publication Of Phase 1 Ziftomenib Combination Data Showing 87% ORR In Venetoclax-Naïve R/R NPM1-m AML

Article summary

Related companies

Comments —